Todos Medical (OTCMKTS:TOMDF) Stock Gains Further Momentum: But Why?
Shares of Todos Medical (OTCMKTS:TOMDF) continued to trend higher on Monday, extending its weekly gain to 12%.
Market Stats
On Monday, TOMDF stock gained 3.90% at $0.0400 with more than 3.77 million shares, compared to its average volume of 10.19 million shares. The stock has moved within a range of $0.0361 – 0.0410 after opening the trade at $0.0361.
2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
The Hillel Yaffe Medical Center has been officially chosen to be the 2nd clinical trial site in Hadera, Israel, for the ongoing Tollovir Phase 2 randomized, double blind, placebo controlled clinical trial for the treatment of hospitalized COVID-19 patients, conducted by Todos Medical (OTCMKTS:TOMDF). Tollovir is an oral 3CL Protease antiviral/anti-cytokine therapeutic candidate focused on blocking the 3CL Protease.
The very first site was revealed in April 2021 – Shaare Zedek Medical Center in Jerusalem, Israel. A thorough, independent review of interim safety and efficacy data is expected to be conducted by the Data Safety Monitoring Board (DSMB) in the last quarter of 2021. The results will play an integral role in determining the next steps towards the therapeutic treatment of COVID-19.
Gerald Commissiong, President & CEO of Todos Medical, is hopeful that the 2nd clinical trial site will boost enrollment in the trial, while expanding the company’s clinical footprint at the same time. The upcoming data analysis is vital when it comes to the clinical development pathway, as they look towards potentially using Tollovir beyond hospitalized patients and potentially evaluating its efficacy in Moderate COVID (pre-hospital) and Long COVID in the future. Dr. Dorit Arad, Chief Scientific Officer of NLC Pharma, the Company’s 3CL protease therapeutic and diagnostics joint venture partner, states that there could be a possibility to even help kids suffering from Covid-19.
Key Quote
“We believe the addition of a 2nd clinical trial site will accelerate enrollment in our ongoing Phase 2 randomized trial and also expand Tollovir’s clinical footprint,” said Gerald Commissiong, President & CEO of Todos Medical. “The upcoming data analysis is quite significant as it will guide the next steps in our clinical development pathway as we look at the potential use of Tollovir beyond hospitalized patients and potentially evaluating its efficacy in Moderate COVID (pre-hospital) and Long COVID in the future.”
Traders Corner
TOMDF stock is trading above the 20-Day and 50-Day Moving averages of $0.0379 and $0.0391 respectively. Moreover, the stock is trading above 200-Day moving average of $0.0399. The stock is up 15% in the past month.
